Trial Profile
Levosimendan following corrective surgery in neonates with congenital heart disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Levosimendan (Primary) ; Cardiotonics
- Indications Congenital heart defects; Low cardiac output
- Focus Therapeutic Use
- 21 Aug 2012 New trial record
- 01 Jul 2012 Results published in Intensive Care Medicine.